ContractSpecial Notice

EZ1 & 2 DNA Blood Isolation Kit and DNA Tissue Kit

DEPARTMENT OF HEALTH AND HUMAN SERVICES NOI-CC-26-000013
Response Deadline
Dec 13, 2025
Deadline passed
Days Remaining
0
Closed
Set-Aside
No Set aside used
Notice Type
Special Notice

Contract Opportunity Analysis

The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to negotiate a sole source contract with Qiagen for the procurement of EZ1 & 2 DNA Blood Isolation Kits and DNA Tissue Kits. These kits are critical for the ongoing clinical research and patient care at the NIH Clinical Center, particularly for Human Leukocyte Antigen (HLA) matching in transplant patients and potential donors. The kits have been extensively tested and are essential for providing high-quality DNA samples necessary for critical Next Generation Sequencing, with an estimated contract value of $29,166.25. Interested parties may submit capability statements by email to valerie.gregorio@nih.gov by 11:00 AM EST on December 13, 2025, referencing NOI-CC-26-000013.

Classification Codes

NAICS Code
334516
Analytical Laboratory Instrument Manufacturing
PSC Code
6550
IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS

Solicitation Documents

1 Files
JOFOC - Qiagen HLA Stndng order - FY26 (1).docx
Word18 KBDec 3, 2025
AI Summary
The National Institutes of Health Clinical Center (NIHCC) Human Leukocyte Antigen (HLA) Lab requires approval for a sole source acquisition of DNA isolation kits from Qiagen, per FAR 6.302-1. These kits are essential for ongoing patient care, specifically for HLA matching of transplant patients and potential donors, with an estimated value of $29,166.25. The justification states that current lab instrumentation is only compatible with Qiagen kits, which have been extensively tested and proven to provide the high-quality DNA samples necessary for critical Next Generation Sequencing. Using an inferior product could delay lifesaving transplants. No alternative vendors for Qiagen products are known, and the anticipated cost is deemed fair and reasonable based on prior orders. The NIHCC HLA Lab emphasizes that inability to acquire these kits would disrupt patient testing, and switching to another source would involve months of retesting, staff retraining, and procedural changes, causing significant harm to ongoing operations.

Related Contract Opportunities

Project Timeline

postedOriginal Solicitation PostedDec 3, 2025
deadlineResponse DeadlineDec 13, 2025
expiryArchive DateDec 28, 2025

Agency Information

Department
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Sub-Tier
NATIONAL INSTITUTES OF HEALTH
Office
NATIONAL INSTITUTES OF HEALTH - CC

Place of Performance

Bethesda, Maryland, UNITED STATES

Official Sources